VXRT - Vaxart Inc Stock Price, Fair Value and News

0.95USD-0.07 (-6.86%)Market Closed

Market Summary

USD0.95-0.07

Market Closed

-6.86%

VXRT Stock Price

View Fullscreen

VXRT RSI Chart

VXRT Valuation

Market Cap

168.0M

Price/Earnings (Trailing)

-2.06

Price/Sales (Trailing)

18.91

EV/EBITDA

-1.94

Price/Free Cashflow

-2.47

VXRT Price/Sales (Trailing)

VXRT Profitability

Operating Margin

-396.34%

EBT Margin

-916.88%

Return on Equity

-146.78%

Return on Assets

-92.19%

Free Cashflow Yield

-40.45%

VXRT Fundamentals

VXRT Revenue

Revenue (TTM)

8.9M

Rev. Growth (Yr)

223.11%

Rev. Growth (Qtr)

-32.79%

VXRT Earnings

Earnings (TTM)

-81.7M

Earnings Growth (Yr)

2.88%

Earnings Growth (Qtr)

-40.53%

Breaking Down VXRT Revenue

Last 7 days

33.8%

Last 30 days

9.2%

Last 90 days

-20.8%

Trailing 12 Months

-26.9%

How does VXRT drawdown profile look like?

VXRT Financial Health

Current Ratio

3.14

VXRT Investor Care

Shares Dilution (1Y)

30.41%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	8.9M	0	0	0
2023	697.0K	2.1M	4.2M	7.4M
2022	471.0K	359.0K	159.0K	107.0K
2021	1.6M	1.2M	1.2M	892.0K
2020	7.4M	7.8M	7.6M	4.0M
2019	8.1M	7.5M	7.7M	9.9M
2018	5.0M	3.8M	3.2M	4.2M
2017	5.3M	3.2M	6.6M	5.8M
2016	0	11.5M	9.4M	7.4M
2015	23.5M	8.4M	13.6M	0
2014	69.5M	68.7M	53.6M	38.5M
2013	24.9M	33.6M	44.4M	52.5M
2012	14.0M	10.9M	11.2M	19.5M
2011	30.4M	29.3M	18.1M	16.1M
2010	0	18.7M	26.8M	35.0M
2009	0	0	0	10.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vaxart Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	cummings james f.	sold (taxes)	-4,279	1.3	-3,292	chief medical officer
Mar 28, 2024	tucker sean	sold (taxes)	-5,072	1.3	-3,902	svp, chief scientific officer
Mar 18, 2024	lee phillip e	acquired	-	-	90,000	chief financial officer
Mar 18, 2024	cummings james f.	acquired	-	-	90,000	chief medical officer
Mar 18, 2024	lo steven	acquired	-	-	250,000	president, chief exec officer
Mar 18, 2024	tucker sean	acquired	-	-	90,000	svp, chief scientific officer
Mar 18, 2024	berg edward b	acquired	-	-	90,000	svp, general counsel
Feb 02, 2024	berg edward b	sold (taxes)	-11,064	1.2	-9,220	svp, general counsel
Feb 02, 2024	cummings james f.	sold (taxes)	-9,558	1.2	-7,965	chief medical officer
Feb 02, 2024	tucker sean	sold (taxes)	-11,064	1.2	-9,220	svp, chief scientific officer

Which funds bought or sold VXRT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	530	163,946	176,274	-%
May 16, 2024	Beacon Capital Management, LLC	unchanged	-	27,744	66,058	0.01%
May 16, 2024	Tidal Investments LLC	new	-	56,484	56,484	-%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	new	-	20,000,000	20,000,000	0.25%
May 15, 2024	LM Advisors LLC	sold off	-100	-3,561	-	-%
May 15, 2024	Curi RMB Capital, LLC	added	5.16	46,148	79,425	-%
May 15, 2024	IHT Wealth Management, LLC	reduced	-0.4	171,554	307,634	0.01%
May 15, 2024	Squarepoint Ops LLC	added	690	232,204	245,908	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	48.74	239,651	340,328	-%
May 15, 2024	STATE STREET CORP	added	25.12	491,632	758,869	-%

Are Funds Buying or Selling VXRT?

Are funds buying VXRT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VXRT

No. of Funds

Unveiling Vaxart Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	4.63%	7,044,971	SC 13G/A
Jan 19, 2024	ra capital management, l.p.	9.1%	15,384,615	SC 13G
Jul 07, 2023	blackrock inc.	1.3%	1,928,709	SC 13G/A
Feb 09, 2023	vanguard group inc	5.35%	7,019,507	SC 13G
Feb 01, 2023	blackrock inc.	6.7%	8,858,225	SC 13G/A
Jan 10, 2023	state street corp	1.83%	2,398,264	SC 13G/A
Mar 10, 2022	state street corp	10.39%	13,072,021	SC 13G/A
Feb 11, 2022	state street corp	8.91%	11,187,642	SC 13G/A
Feb 07, 2022	blackrock inc.	6.7%	8,452,420	SC 13G
Feb 11, 2021	state street corp	8.63%	9,444,967	SC 13G

Recent SEC filings of Vaxart Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
Apr 30, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 18, 2024	PRE 14A	PRE 14A
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4/A	Insider Trading

Peers (Alternatives to Vaxart Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Vaxart Inc News

Latest updates

Vaxart Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-32.8%	2,181,000	3,245,000	2,101,000	1,358,000	675,000	22,000	-	-	85,000	74,000	200,000	112,000	506,000	356,000	265,000	523,000	2,902,000	3,916,000	454,000	85,000	5,407,000
Operating Expenses	30.3%	26,251,000	20,145,000	19,923,000	24,411,000	26,247,000	31,160,000	29,426,000	29,247,000	24,861,000	24,289,000	17,451,000	15,887,000	16,017,000	13,717,000	7,854,000	9,049,000	3,596,000	9,542,000	5,168,000	5,082,000	5,855,000
S&GA Expenses	-100.0%	-	5,440,000	4,921,000	5,598,000	6,625,000	6,447,000	6,960,000	9,321,000	6,658,000	5,754,000	5,042,000	5,150,000	5,944,000	5,126,000	4,190,000	3,896,000	1,990,000	1,331,000	1,455,000	1,375,000	2,026,000
R&D Expenses	29.3%	19,013,000	14,705,000	15,002,000	18,813,000	19,622,000	20,459,000	22,466,000	19,926,000	18,203,000	15,530,000	12,409,000	10,737,000	10,073,000	8,591,000	4,616,000	5,114,000	1,542,000	3,291,000	3,713,000	3,707,000	3,829,000
EBITDA Margin	17.9%	-8.19	-9.97	-19.42	-45.33	-144	-952	-625	-245	-159	-74.16	-50.74	-40.71	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27,000	84,000	97,000	107,000
Income Taxes	-74.1%	45,000	174,000	39,000	19,000	29,000	16,000	16,000	15,000	20,000	18,000	21,000	30,000	38,000	33,000	26,000	26,000	153,000	196,000	31,000	13,000	250,000
Earnings Before Taxes	-41.7%	-24,372,000	-17,201,000	-17,361,000	-22,531,000	-25,111,000	-23,902,000	-29,293,000	-29,415,000	-25,081,000	-20,746,000	-17,562,000	-16,086,000	-15,969,000	-13,828,000	-8,059,000	-8,951,000	-1,144,000	-6,213,000	-5,229,000	-5,624,000	-1,089,000
EBT Margin	17.7%	-9.17	-11.14	-21.39	-49.07	-154	-1,006	-657	-258	-168	-78.88	-54.04	-43.54	-	-	-	-	-	-	-	-	-
Net Income	-40.5%	-24,417,000	-17,375,000	-17,400,000	-22,550,000	-25,140,000	-23,918,000	-29,309,000	-29,430,000	-25,101,000	-20,764,000	-17,583,000	-16,116,000	-16,007,000	-13,861,000	-8,085,000	-8,977,000	-1,297,000	-6,409,000	-5,260,000	-5,637,000	-1,339,000
Net Income Margin	17.7%	-9.20	-11.18	-21.42	-49.11	-154	-1,007	-657	-258	-168	-79.00	-54.15	-43.64	-	-	-	-	-	-	-	-	-
Free Cashflow	-58.9%	-21,322,000	-13,417,000	-15,283,000	-17,925,000	-25,699,000	-33,053,000	-16,643,000	-28,225,000	-26,459,000	-16,829,000	-15,591,000	-15,362,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.4%	89.00	92.00	106	123	130	154	175	181	200	221	241	229	206	153	155	64.00	53.00	37.00	43.00	37.00	36.00
Current Assets	-2.7%	44.00	46.00	57.00	71.00	76.00	99.00	120	138	154	169	192	189	175	129	136	46.00	34.00	18.00	21.00	17.00	15.00
Cash Equivalents	-23.1%	27.00	35.00	33.00	43.00	48.00	44.00	51.00	91.00	123	144	167	165	157	127	133	44.00	30.00	14.00	20.00	16.00	8.00
Net PPE	-5.4%	11.00	12.00	13.00	14.00	14.00	16.00	12.00	9.00	8.00	7.00	5.00	4.00	2.00	1.00	1.00	0.00	0.00	0.00	1.00	2.00	2.00
Goodwill	0%	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-3.1%	33.00	34.00	34.00	38.00	40.00	43.00	53.00	38.00	34.00	34.00	36.00	29.00	30.00	29.00	23.00	24.00	21.00	24.00	24.00	21.00	24.00
Current Liabilities	2.9%	14.00	14.00	11.00	14.00	16.00	18.00	22.00	16.00	11.00	11.00	13.00	13.00	12.00	12.00	10.00	11.00	7.00	9.00	9.00	7.00	9.00
Shareholder's Equity	-3.7%	56.00	58.00	72.00	85.00	90.00	111	122	143	166	188	205	200	176	123	132	40.00	31.00	13.00	19.00	16.00	13.00
Retained Earnings	-6.0%	-433	-409	-392	-374	-352	-327	-303	-273	-244	-219	-198	-181	-164	-148	-135	-126	-117	-116	-110	-104	-99.35
Additional Paid-In Capital	4.8%	490	468	464	460	442	438	426	417	411	407	404	381	341	272	267	167	142	130	125	119	111
Accumulated Depreciation	13.2%	8.00	7.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	15.0%	177	153	152	152	136	134	126	126	126	126	120	121	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	110	-	-	-	394	-	-	-	913	-	-	-	842	-	-	-	8.00	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-56.7%	-21,191	-13,521	-15,001	-17,471	-24,460	-29,152	-14,615	-25,899	-25,113	-15,814	-14,267	-13,159	-16,592	-10,766	-9,255	-521	-3,208	-3,792	-4,328	-317	-4,653
Share Based Compensation	10.8%	4,116	3,715	3,843	3,927	2,647	3,393	3,643	3,421	3,130	2,913	2,099	2,604	1,251	487	915	2,860	96.00	137	146	180	164
Cashflow From Investing	-133.3%	-5,024	15,104	4,970	-1,583	25,461	15,801	-31,073	-8,875	3,732	-8,177	-4,412	-15,949	-20,559	-902	-308	-9.00	-1.00	-12.00	-127	-159	-552
Cashflow From Financing	27668.2%	18,195	-66.00	-8.00	13,897	1,420	8,596	4,988	2,838	1,040	505	20,644	37,063	67,592	5,100	98,613	15,059	19,542	-2,228	7,755	8,310	2,123

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VXRT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues	$ 2,181	$ 675
Operating expenses:
Research and development	19,013	19,622
General and administrative	7,238	6,625
Total operating expenses	26,251	26,247
Operating loss	(24,070)	(25,572)
Other income (expense):
Interest income	503	642
Non-cash interest expense related to sale of future royalties	(804)	(178)
Other expense, net	(1)	(3)
Loss before income taxes	(24,372)	(25,111)
Provision for income taxes	45	29
Net loss	$ (24,417)	$ (25,140)
Net loss per share - basic and diluted (in dollars per share)	$ (0.14)	$ (0.19)
Shares used to compute net loss per share - basic and diluted (in shares)	168,811,095	135,213,196
Comprehensive loss:
Net loss	$ (24,417)	$ (25,140)
Unrealized (loss) gain on available-for-sale investments, net of tax	(9)	229
Comprehensive loss	(24,426)	(24,911)
Non Cash Royalty Revenue [Member]
Revenues	585	278
Government Contract [Member]
Revenues	1,596	0
Grant [Member]
Revenues	$ 0	$ 397

VXRT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 26,735	$ 34,755
Short-term investments	9,929	4,958
Accounts receivable	556	3,008
Prepaid expenses and other current assets	7,064	2,815
Total current assets	44,284	45,536
Property and equipment, net	11,102	11,731
Right-of-use assets, net	23,753	24,840
Intangible assets, net	4,106	4,289
Goodwill	4,508	4,508
Other long-term assets	917	926
Total assets	88,670	91,830
Current liabilities:
Accounts payable	3,978	1,584
Other accrued current liabilities	4,980	5,634
Current portion of operating lease liability	2,799	2,703
Current portion of liability related to sale of future royalties	2,360	3,803
Total current liabilities	14,117	13,724
Operating lease liability, net of current portion	16,691	17,385
Liability related to sale of future royalties, net of current portion	1,863	2,623
Other long-term liabilities	309	293
Total liabilities	32,980	34,025
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock: $0.0001 par value; 250,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 177,187,965 shares issued and 176,523,042 shares outstanding as of March 31, 2024 and 153,959,853 shares issued and 153,452,833 shares outstanding as of December 31, 2023	18	15
Additional paid-in capital	490,221	467,731
Treasury stock at cost, 664,923 shares as of March 31, 2024 and 507,020 shares as of December 31, 2023	(548)	(366)
Accumulated deficit	(433,991)	(409,574)
Accumulated other comprehensive loss	(10)	(1)
Total stockholders’ equity	55,690	57,805
Total liabilities and stockholders’ equity	$ 88,670	$ 91,830

About Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

CEO	Mr. Cezar Andrei Floroiu M.B.A.
WEBSITE	https://vaxart.com
INDUSTRY	Biotechnology
EMPLOYEES	164

Vaxart Inc Frequently Asked Questions

What is the ticker symbol for Vaxart Inc? What does VXRT stand for in stocks?

VXRT is the stock ticker symbol of Vaxart Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaxart Inc (VXRT)?

As of Fri May 17 2024, market cap of Vaxart Inc is 168 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VXRT stock?

You can check VXRT's fair value in chart for subscribers.

What is the fair value of VXRT stock?

You can check VXRT's fair value in chart for subscribers. The fair value of Vaxart Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vaxart Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VXRT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vaxart Inc a good stock to buy?

The fair value guage provides a quick view whether VXRT is over valued or under valued. Whether Vaxart Inc is cheap or expensive depends on the assumptions which impact Vaxart Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VXRT.

What is Vaxart Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, VXRT's PE ratio (Price to Earnings) is -2.06 and Price to Sales (PS) ratio is 18.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VXRT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vaxart Inc's stock?

In the past 10 years, Vaxart Inc has provided -0.294 (multiply by 100 for percentage) rate of return.